Novel FDA-approved zavegepant drug for treating migraine.
Annals of medicine and surgery (2012), ISSN: 2049-0801, Vol: 86, Issue: 2, Page: 923-925
2024
- 10Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures10
- Readers10
- 10
- Mentions2
- News Mentions1
- News1
- References1
- Wikipedia1
Most Recent News
Studies from DOW University of Health Sciences Further Understanding of Migraine (Novel FDA approved zavegepant drug for treating migraine)
2024 JAN 02 (NewsRx) -- By a News Reporter-Staff News Editor at CDC & FDA Daily -- Investigators publish new report on migraine. According to
Review Description
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret's overall safety profile remains acceptable.
Bibliographic Details
http://dx.doi.org/10.1097/ms9.0000000000001620; http://www.ncbi.nlm.nih.gov/pubmed/38333255; https://journals.lww.com/10.1097/MS9.0000000000001620; https://dx.doi.org/10.1097/ms9.0000000000001620; https://journals.lww.com/annals-of-medicine-and-surgery/abstract/9900/novel_fda_approved_zavegepant_drug_for_treating.1309.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know